Figure 10. Combination treatment with IFN-α-2b and ixazomib reduces tumor volume in vivo.

Female Balb/c nu/nu (athymic) mice were injected s.c. in the right flank with 2 × 10⁶ human A375 melanoma cells (day 0). Once tumors were palpable, mice were randomized to one of four treatment groups: 1- PBS (n = 11), 2- IFN-α-2b (2 × 10⁴ units/day, intraperitoneal injection; n = 12), 3- ixazomib (7.0 mg/kg twice weekly, oral gavage; n = 12), or 4- IFN-α-2b and ixazomib combined (n = 13). A. Bidimensional tumor measurements were obtained three times weekly using microcalipers. Data represented as mean ± standard error of the mean. B. Representative image of tumor samples collected at the completion of the study.